- Home
- RPRX vs CHWY Comparison
RPRX vs CHWY Comparison
Compare RPRX & CHWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- CHWY
- Stock Information
- Founded
- RPRX 1996
- CHWY 2010
- Country
- RPRX United States
- CHWY United States
- Employees
- RPRX N/A
- CHWY N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- CHWY Catalog/Specialty Distribution
- Sector
- RPRX Health Care
- CHWY Consumer Discretionary
- Exchange
- RPRX Nasdaq
- CHWY Nasdaq
- Market Cap
- RPRX 14.2B
- CHWY 13.4B
- IPO Year
- RPRX 2020
- CHWY 2019
- Fundamental
- Price
- RPRX $32.20
- CHWY $36.79
- Analyst Decision
- RPRX Strong Buy
- CHWY Buy
- Analyst Count
- RPRX 4
- CHWY 23
- Target Price
- RPRX $42.50
- CHWY $38.56
- AVG Volume (30 Days)
- RPRX 4.5M
- CHWY 6.6M
- Earning Date
- RPRX 05-08-2025
- CHWY 05-28-2025
- Dividend Yield
- RPRX 2.73%
- CHWY N/A
- EPS Growth
- RPRX N/A
- CHWY 911.11
- EPS
- RPRX 1.91
- CHWY 0.91
- Revenue
- RPRX $2,263,576,000.00
- CHWY $11,861,335,000.00
- Revenue This Year
- RPRX $31.56
- CHWY $7.87
- Revenue Next Year
- RPRX $5.94
- CHWY $6.92
- P/E Ratio
- RPRX $16.84
- CHWY $40.44
- Revenue Growth
- RPRX N/A
- CHWY 6.40
- 52 Week Low
- RPRX $24.05
- CHWY $14.85
- 52 Week High
- RPRX $34.20
- CHWY $40.09
- Technical
- Relative Strength Index (RSI)
- RPRX 51.13
- CHWY 60.64
- Support Level
- RPRX $31.58
- CHWY $33.33
- Resistance Level
- RPRX $32.73
- CHWY $36.95
- Average True Range (ATR)
- RPRX 0.93
- CHWY 1.85
- MACD
- RPRX 0.06
- CHWY 0.41
- Stochastic Oscillator
- RPRX 82.74
- CHWY 97.62
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About CHWY Chewy Inc.
Chewy is the largest e-commerce pet care retailer in the US, generating $11.2 billion in 2023 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.